FI3345604T3 - Nalmefeeni alkoholikulutuksen vähentämiseksi spesifisissä kohdepopulaatioissa - Google Patents

Nalmefeeni alkoholikulutuksen vähentämiseksi spesifisissä kohdepopulaatioissa Download PDF

Info

Publication number
FI3345604T3
FI3345604T3 FIEP17206034.5T FI17206034T FI3345604T3 FI 3345604 T3 FI3345604 T3 FI 3345604T3 FI 17206034 T FI17206034 T FI 17206034T FI 3345604 T3 FI3345604 T3 FI 3345604T3
Authority
FI
Finland
Prior art keywords
nalmefene
use according
alcohol
patient
day
Prior art date
Application number
FIEP17206034.5T
Other languages
English (en)
Finnish (fi)
Inventor
Lars Torup
Afsaneh Abbariki
Anna Bladström
Christine Persson
Didier Meulien
Per Sørensen
Thomas Jensen
Jette Østergaard
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48703496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3345604(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of FI3345604T3 publication Critical patent/FI3345604T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
FIEP17206034.5T 2012-06-27 2013-06-27 Nalmefeeni alkoholikulutuksen vähentämiseksi spesifisissä kohdepopulaatioissa FI3345604T3 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261664804P 2012-06-27 2012-06-27
US201261721539P 2012-11-02 2012-11-02
US201261736740P 2012-12-13 2012-12-13
US201361788810P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
FI3345604T3 true FI3345604T3 (fi) 2023-07-28

Family

ID=48703496

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP17206034.5T FI3345604T3 (fi) 2012-06-27 2013-06-27 Nalmefeeni alkoholikulutuksen vähentämiseksi spesifisissä kohdepopulaatioissa

Country Status (35)

Country Link
US (4) US20140005217A1 (enExample)
EP (5) EP2866808B1 (enExample)
JP (3) JP6258933B2 (enExample)
KR (1) KR20150023396A (enExample)
CN (1) CN104411313A (enExample)
AU (1) AU2013283281B2 (enExample)
BR (1) BR112014032555A2 (enExample)
CA (1) CA2874703C (enExample)
CL (1) CL2014003484A1 (enExample)
CO (1) CO7160087A2 (enExample)
CY (3) CY1118579T1 (enExample)
DK (3) DK2866808T3 (enExample)
EA (1) EA029908B1 (enExample)
ES (4) ES2950492T3 (enExample)
FI (1) FI3345604T3 (enExample)
HK (1) HK1255683A1 (enExample)
HR (4) HRP20230762T8 (enExample)
HU (4) HUE063313T2 (enExample)
IL (1) IL236035B (enExample)
LT (3) LT2866808T (enExample)
ME (2) ME03030B (enExample)
MX (1) MX371373B (enExample)
MY (1) MY166914A (enExample)
NZ (1) NZ702191A (enExample)
PH (1) PH12014502798A1 (enExample)
PL (4) PL3345604T3 (enExample)
PT (3) PT3345604T (enExample)
RS (2) RS57046B1 (enExample)
RU (1) RU2665373C2 (enExample)
SG (1) SG11201408704WA (enExample)
SI (3) SI3138564T1 (enExample)
SM (3) SMT201800164T1 (enExample)
UA (1) UA114199C2 (enExample)
WO (1) WO2014001427A1 (enExample)
ZA (1) ZA201409525B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
JP6419780B2 (ja) * 2013-04-17 2018-11-07 ハー・ルンドベック・アクチエゼルスカベット 睡眠障害患者の治療のためのナルメフェン
CA2946698A1 (en) 2014-04-22 2015-10-29 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
US20170071590A1 (en) * 2015-09-10 2017-03-16 Suture Armor Llc Suture anchor
KR102699603B1 (ko) 2018-04-20 2024-08-29 삼성전자주식회사 반도체 메모리 소자

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3814768A (en) 1971-11-26 1974-06-04 Lewenstein E 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
EP1423116A1 (en) * 2001-08-14 2004-06-02 Biotie Therapies Corp. Method of treating alcoholism or alcohol abuse
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
EA019331B1 (ru) 2009-05-25 2014-02-28 Х. Лундбекк А/С Получение налмефена гидрохлорида из налтрексона
AU2011325563B2 (en) 2010-11-05 2015-08-20 H. Lundbeck A/S Method for the manufacturing of naltrexone
CA2829280C (en) 2011-03-31 2016-05-24 Imuneks Farma Ilac Sanayi Ve Ticaret A.S. Compositions of opioid antagonists and their use for treating scleroderma
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations

Also Published As

Publication number Publication date
ES2663532T3 (es) 2018-04-13
JP6857684B2 (ja) 2021-04-14
PL3345604T3 (pl) 2023-08-28
ES2609122T3 (es) 2017-04-18
SI3138564T1 (en) 2018-04-30
EP2866808A1 (en) 2015-05-06
RU2014151156A (ru) 2016-08-20
ME02587B (me) 2017-06-20
CY1126140T1 (el) 2023-11-15
ES3014068T3 (en) 2025-04-16
SMT201800164T1 (it) 2018-07-17
SMT201600471T1 (it) 2017-03-08
SMT201600471B (it) 2017-03-08
EA201492152A1 (ru) 2015-11-30
HRP20230762T8 (hr) 2024-01-05
MX2014015488A (es) 2015-03-06
RS55456B1 (sr) 2017-04-28
IL236035A0 (en) 2015-01-29
EP3345604A1 (en) 2018-07-11
US20140005216A1 (en) 2014-01-02
HRP20250329T1 (hr) 2025-05-09
PH12014502798A1 (en) 2015-02-09
US20160375007A1 (en) 2016-12-29
PT2866808T (pt) 2017-01-03
US9642849B2 (en) 2017-05-09
HK1255683A1 (en) 2019-08-23
EP4223296A3 (en) 2023-09-27
JP2019163275A (ja) 2019-09-26
LT2866808T (lt) 2017-01-10
CY1118579T1 (el) 2017-07-12
AU2013283281A1 (en) 2014-12-11
DK3138564T3 (en) 2018-03-26
JP2015521647A (ja) 2015-07-30
HUE063313T2 (hu) 2024-01-28
HUE031110T2 (en) 2017-06-28
EP3345604B1 (en) 2023-06-07
UA114199C2 (uk) 2017-05-10
HUE070621T2 (hu) 2025-06-28
SI3345604T1 (sl) 2023-08-31
DK2866808T3 (en) 2017-01-16
LT3138564T (lt) 2018-04-10
PL3138564T3 (pl) 2018-06-29
KR20150023396A (ko) 2015-03-05
MY166914A (en) 2018-07-24
RU2665373C2 (ru) 2018-08-29
SI2866808T1 (sl) 2017-01-31
MX371373B (es) 2020-01-28
US10034874B2 (en) 2018-07-31
CA2874703C (en) 2022-08-23
CO7160087A2 (es) 2015-01-15
WO2014001427A1 (en) 2014-01-03
EP4541421A3 (en) 2025-06-18
JP6258933B2 (ja) 2018-01-10
US20180028526A1 (en) 2018-02-01
HUE036272T2 (hu) 2018-06-28
EP4223296A2 (en) 2023-08-09
CN104411313A (zh) 2015-03-11
CA2874703A1 (en) 2014-01-03
JP2018039810A (ja) 2018-03-15
EP4541421A2 (en) 2025-04-23
DK3345604T3 (da) 2023-07-24
US20140005217A1 (en) 2014-01-02
PL2866808T3 (pl) 2017-04-28
PT3138564T (pt) 2018-04-03
AU2013283281B2 (en) 2017-04-20
EP3138564B1 (en) 2018-01-31
RS57046B1 (sr) 2018-05-31
ES2950492T3 (es) 2023-10-10
PL4223296T3 (pl) 2025-04-14
BR112014032555A2 (pt) 2017-06-27
EA029908B1 (ru) 2018-05-31
EP3138564A1 (en) 2017-03-08
CL2014003484A1 (es) 2015-02-27
HRP20180363T1 (hr) 2018-04-20
EP4223296B1 (en) 2025-01-29
SG11201408704WA (en) 2015-01-29
IL236035B (en) 2018-12-31
HK1208185A1 (en) 2016-02-26
NZ702191A (en) 2017-06-30
HRP20230762T1 (hr) 2023-10-13
CY1120097T1 (el) 2018-12-12
LT3345604T (lt) 2023-08-10
ZA201409525B (en) 2016-08-31
PT3345604T (pt) 2023-07-17
ME03030B (me) 2018-10-20
HRP20161717T1 (hr) 2017-02-10
EP4223296C0 (en) 2025-01-29
EP2866808B1 (en) 2016-11-02

Similar Documents

Publication Publication Date Title
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX385798B (es) Composiciones orales que contienen un ester de 17-hidroxiprogesterona y metodos relacionados.
WO2012079092A3 (en) Testosterone undecanoate compositions
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
NZ596879A (en) Tamper resistant dosage form comprising a matrix and melt - extruded particulates comprising a drug
MY194947A (en) Intranasal pharmaceutical dosage forms comprising naloxone
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
MX2009003518A (es) Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
HRP20171678T1 (hr) Postupci za smanjenje prejedanja ili kompulzivnog jedenja
JP2018039810A5 (enExample)
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
HRP20230762T1 (hr) Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama
JP2015521647A5 (enExample)
IN2014MN02156A (enExample)
NZ602032A (en) Oral b12 therapy
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
MX337593B (es) Gemcabeno y derivados para tratar la pancreatitis.
RU2017136693A (ru) Способы поддержания, лечения или улучшения когнитивной функции
RU2012114097A (ru) Терапевтический агент против хронической боли
PH12015502560B1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease
UA96878C2 (ru) Средство для лечения заболеваний сердечно-сосудистой системы и регулирования метаболических процессов
UA65489U (ru) Способ профилактики развития дисфункции плаценты у женщин группы риска